He is one of the founders of ProQR, but even long before that Gerard Platenburg was involved in the development of RNA therapies. Even so, after decades of working on them he still gets enthusiastic when talking about RNA.
… Officer role, with leadership oversight of Axiomer ® RNA-editing platform technology John Maraganore, PhD, former … provide strategic oversight of ProQR’s proprietary Axiomer RNA-editing platform technology. He is the scientific … including further building out the Company’s Axiomer RNA-editing technology as a value-generating platform. Smital …
… 10 (LCA10). Presentation title : Proof-of-concept for RNA-editing oligonucleotide QR-110 for treatment of inherited … clinical studies Poster presentation on Axiomer ® RNA editing technology A presentation will be delivered by … computational analytics of ProQR on the Axiomer ® RNA editing technology. Poster title: Structure-based …
… with LCA10 and preclinical data for ProQR’s Axiomer ® RNA-editing technology. Abstract titles: ○ Proof-of-concept for RNA-editing oligonucleotide QR-110 for treatment of inherited … ® EONs are designed to recruit an endogenously expressed RNA editing system called ADAR, which it can direct to the …
ProQR is accelerating the development of its Axiomer® RNA base-editing technology platform across multiple therapeutic areas and will provide an update on first targets in H2 2022
Company plans to discuss findings from sepofarsen Illuminate trial w
